

Original Research Article

Laboratory Evaluation of Clinical Bacterial Isolates for Detection of Carbapenemases-Producing *Enterobacteriaceae* in Kano, North West, Nigeria.

ABSTRACT

The spread of carbapenemase-producing *Enterobacteriaceae* is a global problem; however, no exact data on the epidemiology of carbapenemase in Kano, Northern Nigeria is available. The study was aimed to detect the occurrence and prevalence of carbapenemase production among clinical bacterial isolates in Aminu Kano Teaching Hospital, Kano, Nigeria. From March to August 2014, a total of 100 clinical bacterial isolates comprising of *E. coli* (44), *Klebsiella pneumoniae* (27), *Proteus mirabilis* (19) *Pseudomonas aeruginosa* (6) and *Proteus vulgaris* (4) were screened for susceptibility to 3rd generation Cephalosporins using Kirby Baure disc diffusion method and for carbapenemase production using Modified Hodges Test. Result obtained showed that 7(7%) of the isolates were found to produce carbapenemase. Highest prevalence of carbapenemase production was found in *E. coli* (9.09%) followed by *Klebsiella pneumoniae* (7.40%) *Proteus mirabilis* (5.26%) and none were found in *Proteus vulgaris* (0%) and *Pseudomonas aeruginosa* (0%). Urine samples were found to be with the highest prevalence of 57.1% when compared with sputum (42.9%). This showed that carbapenemase-mediated resistance occurred in Kano state and uncontrolled spread may lead to treatment failure.

Keywords: Antimicrobials, Detection, Carbapenemases, Bacterial Isolates, Kano

1. INTRODUCTION

Antibiotic resistance remains a major global public health problem that leads to increasing healthcare costs, extra length of hospital stay, and treatment failures [1]. An emerging problem is the spread and increasing prevalence of carbapenemase-producing gram-negative bacteria. For example, outbreaks of *Klebsiella pneumoniae* carbapenemase (KPC)-positive *K. pneumonia* occurred in the USA in 2001 and subsequently spread throughout the world; New Delhi metallo- β -lactamase (NDM-1)-positive *K. pneumoniae* was imported from India and spread to the United Kingdom in 2010 [2]. *Enterobacteriaceae* are inhabitants of the intestinal flora and are among the most common human pathogens, causing

infections such as cystitis and pyelonephritis with fever, septicemia, pneumonia, peritonitis, meningitis, and device-associated infections. *Enterobacteriaceae* are the source of community- and hospital-acquired infections. They have the propensity to spread easily between humans (hand carriage, contaminated food and water) and to acquire genetic material through horizontal gene transfer, mediated mostly by plasmids and transposons [3].

The Carbapenems namely imipenem, meropenem, ertapenem, and doripenem are the antimicrobials of last resort used in treating infections due to highly drug resistant bacteria [4]. These antimicrobial agents became crucial in the management of life-threatening healthcare-associated and community acquired infections [5]. Carbapenems are no longer fully effective in the CRE epidemic. The paucity of novel antimicrobials in development escalates the antimicrobial resistance problem, severely reducing the available therapeutic choices [6].

The mechanism of carbapenemase production is the most prominent mechanism of carbapenem resistance and is distinct from other antimicrobial resistance such as impaired permeability due to porin mutations, although the susceptibility patterns for carbapenemase producing isolates and those with porin mutations can be identical [7]. CRE infections pose a serious threat to public health due to high mortality rates, resistance to commonly used antibiotics, limited treatment options, and the potential for widespread dissemination, mortality rates of up to 40% to 50% have been reported [8]. Early recognition of producers of carbapenemases has become mandatory and crucial for controlling the spread of carbapenemase-producing bacteria as treatment of infections caused by pathogens producing carbapenemases, poses a serious challenge because these infections are resistant to all commonly used antibiotics [9].

Their rapid dissemination is worrisome and necessitates not just surveillance study but also studying occurrence and prevalence in a hospital setting to formulate a policy of therapy. Hence this study was carried out in order to detect the occurrence and prevalence of carbapenemase production among clinical bacterial isolates in Aminu Kano Teaching Hospital, Kano, Nigeria.

2. MATERIALS AND METHODS

2.1 Collection of Isolates

A total of 100 clinical bacterial isolates of *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus spp*, and *Serratia spp* and the control strain *E.coli* ATCC 25922 were collected from the Pathology Department of Aminu Kano Teaching Hospital (AKTH), Kano over a period of six months.

2.2 Susceptibility Testing

The antimicrobial susceptibility pattern of the isolates to Cefotaxime and Ceftriaxone was determined using Kirby Baure disc diffusion method [10].

2.3 Screening of Pathogens for Carbapenemases

The bacterial clinical isolates that were resistant to any or both of the above 3rd generation cephalosporin were screened for carbapenemases [11]. In this method carbapenem antibiotic, meropenem and imipenem discs (10µg, Oxoid, England) were used. The antibiotic discs were placed on the surface of inoculated Mueller Hinton Agar (MHA) plates using a sterile forceps. The discs were placed about 30mm apart and the plates were incubated for 24 hours at 37°C after which zones of inhibitions were read. Isolates that showed a zone of inhibition ≤ 19 mm in diameter for meropenem or ≤ 19 mm in diameter for imipenem were considered as suspected carbapenemase producers and were subjected to confirmatory test by the Modified Hodges Test [10].

2.4 Confirmation of Carbapenemases (Modified Hodges Test)

In this method, a 0.5 McFarland suspension of *E.coli* ATCC 25922 was prepared in 5ml of saline and the suspension was diluted to 1:10 by adding 0.5 Mc Farland to 4.5ml of saline, this was then used to evenly inoculate the surface of MHA plates using a sterile cotton swab. Meropenem disc (10µg, Oxoid, England) was placed on the center of MHA using sterile forcep, by means of a sterilized wire loop, the test organism was streaked from the edge of the disc to the edge of the plate. The plates were incubated at 37°C for 24 hours. After incubation MHT positive test showed a cover leaf like indentation of the *Escherichia coli* 25922 growing along the test organism growth streaked within the disk diffusion zone.

While MHT Negative test showed no growth of the *E.Coli* 25922 along the test organism growth streaked within the disk diffusion zone [11].

3. RESULTS

The 100 clinical bacterial isolates used during this research work analyzed were confirmed, using various biochemical tests, to be *Escherichia coli* (44) as the most frequent spp. followed by *Klebsella pneumoniae* (27), *Proteus mirabilis* (19), *Pseudomonas aeruginosa* (6) and the least frequent spp.is *Proteus vulgaris* (4).

On subjecting the above clinical isolates to susceptibility testing using kirby bauer disc diffusion method, a total of 47 (47%) isolates were resistant to cefotaxime, 23 (23%) were resistant to ceftriaxone. Out of 49 isolates that were resistant to any or both of the tested cephalosporin 12(24.5%) were resistant to meropenem and 5(41.67) were resistant to imipenem

Generally 12 (24.5%) were carbapenem resistant, (i.e. they are resistant to either meropenem, imipenem or both) these include *E. coli* 6 (50%), *K. pneumoniae* 4 (33.3%), *P. mirabilis* 2(16.7%), *P. vulgaris* 0(0%) and *Pseudomonas aeruginosa* 0(0%)

These carbapenem resistant isolates are the suspected carbapenemase producers and they are subjected to a confirmatory tests using modified hodge test in which 7 out of the 12 were confirmed to be carbapenemase producers which include *E. coli* 4(9.09 %), *K.pneumoniae*, 2(7.40%), *P. mirabilis* 1 (5.26%), *P. vulgaris* 0 (0%) and *P.aeruginosa* 0(0%)

Table 1: Prevalence of Carbapenemase among the Clinical Bacterial Isolates

S/N	Clinical Bacterial Isolates	No. of Isolates Screened	No. of Isolates Producing Carbapenemase	% Prevalence
1.	<i>E.coli</i>	44	4	9.09

2	<i>K.pneumoniae</i>	27	2	7.40
3	<i>P.mirabilis</i>	19	1	5.26
4	<i>P. vulgaris</i>	4	0	0
5	<i>P. aeruginosa</i>	6	0	0
Total		100	7	7

105

106 **Table 2: Susceptibility of the Isolates to Cefotaxime and Ceftriaxone**

S/N	Bacterial Isolates	No. Screened	No. Susceptible to Cefotaxime (%)	No. Susceptible to Ceftriaxone(%)
1.	<i>E.coli</i>	44	24(55)	28(64)
2	<i>K.pneumoniae</i>	27	8(30)	15(56)
3	<i>P.mirabilis</i>	19	13(68)	17(89)
4	<i>P. vulgaris</i>	4	0(0)	1(25)
5	<i>P. aeruginosa</i>	6	3(50)	3(50)
Total		100	48(48)	64(64)

107

108 **Table 3: Susceptibility of the Isolates to Meropenem and Imipenem**

S/N	Bacterial isolates	No. Screened	No. Susceptible to Meropenem (%)	No. Susceptible to Imipenem (%)
1.	<i>E.coli</i>	21	17(81)	9(43)
2	<i>K.pneumoniae</i>	16	14(88)	10(63)

3	<i>P.mirabilis</i>	5	5(100)	3(60)
4	<i>P. vulgaris</i>	4	3(75)	4(100)
5	<i>P. aeruginosa</i>	3	2(67)	3(100)
Total		49	41 (84%)	29 (59%)

4. DISCUSSION

The study showed that carbapenemase producing organisms (CPO) exist in some of clinical bacterial isolates in Kano State, with a prevalence of about 7% this is in agreement with the findings of [12] which reported carbapenemase production with a prevalence of 14.0% in 2010. Few months later another research published by [13] reported a decreased prevalence of 13.32% in Kano Nigeria, this shows that the carbapenemase producers exist among clinical bacterial isolates in Kano State, but with a low prevalence. This may be due to unavailability and cost of the antibiotics in Kano where only few can afford to buy it, and they are prescribed for only life threatening infections.

A higher prevalence was reported elsewhere for example [14] also reported 59% in New York. This high difference in prevalence could be as a result of the aforementioned reasons.

The high prevalence among *E.coli* (9.09%) and *K.pneumoniae* (7.40%) agrees with the report of [15] which reported that carbapenem resistance has been cited in up to 4.0% of *Escherichia coli* and 10.8% *Klebsella Pneumoniae* isolates, reported to the national health care safety network. The high prevalence among *E.coli* (9.09%) and the least prevalence among *P.aeruginosa* (0%) also tally with the result of [12] which reported that highest number of carbapenemase producers (MBLtype) was found in *E.coli* (89.7%) and the least prevalence was recorded for *P.aeruginosa* (55.0%).

Antimicrobial susceptibility pattern of the isolates shows that out of 100 isolates tested 48(48%) were sensitive to cefotaxime, and 64(64%) were sensitive to ceftriaxone, and out of 49 isolates tested for carbapenem susceptibility 41 isolates (83.7%) were sensitive to meropenem, and 29 isolates (59.2%)

were sensitive to imipenem, this also agrees with the result of [16] which reported a high sensitivity (100%) of *P.aeruginosa* to meropenem and a lower sensitivity (75%) to imipenem.

Based on clinical samples urine was found to have the highest prevalence (57.1%) of carbapenemase producers, followed by sputum (42.9%) this may be due to the fact that urinary tract infection is on increase worldwide and a multitude of antibiotic is used in their treatment. The reports of urinary pathogen's resistant to wide range of antibiotics in Kano, Nigeria mediated by extended spectrum beta Lactamases, AmpC beta lactamases and carbapenemases have been reported by [17]; [13] and [12] respectively

5. CONCLUSION

Infections with CRE are an emerging clinical threat and from the findings obtained from this study it is concluded that carbapenemases occurred among clinical bacterial isolates in Kano State raising fears of resistance to a multitude of antibiotics in the treatment of clinical infection

6. RECOMMENDATIONS

The Carbapenems should not be routinely used as first-line therapy unless the pathogen is multidrug-resistant and is known to be susceptible to these agents. Due to the growing threat of CRE infections in the healthcare setting, it is important for pharmacists and clinicians to be familiar with antimicrobial therapy options, risk factors, and diagnostic indicators. Development of new antimicrobials is needed, in light of limited data with current treatment options and growing resistance. Prevention strategies and good infection control programs should be incorporated at the healthcare system level to limit the transmission of CRE within the hospital. A concerted global commitment to the intelligent use of antimicrobials, better antibiotic stewardship, the implementation of effective infection control strategies, and the development of more effective therapies are desperately

7. LIMITATION OF THE STUDY

Limitation of our study is that the clinical bacterial isolates were not screened for various types of carbapenemases such as MBLs carbapenemases. Also the sample size was relatively small and a

single-center design was used. The gram-negative bacteria were not tested for *bla* KPC due to lack of equipment.

ETHICAL ISSUES

Ethical approval and administrative clearance for the study were obtained from the ethical committee of Aminu Kano Teaching Hospital, Kano.

REFERENCES

1. Multidrug antibiotic resistance increasing in Europe. ECDC, 2012, http://www.ecdc.europa.eu/en/press/news/layouts/forms/News_DispForm.aspx?ID=563&List=8db7286c-fe2d-476c-9133-18ff4cb1b568.
2. Marra A. NDM-1: A local clone emerges with worldwide aspirations. *Future Microbiology*. 2011; 6(2):137–141. [PubMed]
3. Pitout JD, Laupl and KB Extended-spectrum β -lactamase-producing *Enterobacteriaceae*: an emerging public health concern. *Lancet Infect Dis*. 2008; 8:159–66 10.1016/S1473-3099(08)70041-0 [PubMed] [Cross Ref]
4. Richard, E .Carbapenemase Producing Enterobacteriaceae Report.*Emerge Infect Dis*, 2013. 14;(8)180-192.
5. Boucher, H., Talbot,G., Bradley, J., Edwards, J. and Ricco E. Bad Bugs, No Drugs No Escape: An Update From the Infectious Disease Society of America. *Clin infect dis*.2009. 2: (4) 8-12.
6. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL: Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clin Microbiol Rev* 2012, 25:682–707.
7. Paterson, D.L. and Bonomo, R.A .Extended Spectrum B-lactamase: A Clinical Update.*Clin Microbial Rev*.2005. 18: (4) 657-76.
8. Radwa, E.S.,Juliek,C. and Ashley S .Carbapenem Resistant Enterobacteriaceae:An Emerging Threat. *Us pharm*, 2013. 38:(12)HS2-HS5.

- 187 9. Yusuf, I., Magashi, A.M., Firdausi, F.S., Shariff, A.A.,Getso, M.I., Bala, J.A. and Aliyu,
188 I.A. Phenotypic Detection of Carbapenemases in Members of Enterobacteriaceae in
189 Kano Nigeria. *International Journal Of Science And Technology*, 2012. (2) 11.
- 190 10. Clinical And Laboratory Standards Institute. Performance Standards For Antimicrobial
191 Susceptibility Testing. 22nd informational supplement, 2013. M 100-S22.
- 192 11. Clinical and Laboratory Standards Institute. Guidance for Control of Infections
193 with Carbapenem Resistant or Carbapenemase Producing – Enterobacteriaceae in
194 Acute Care Facilities, 2010.
- 195 12. Yusuf I., Arzai, A.H., Getso, M., Shariff, A. and Haruna, M. Emergence of Carbapenem
196 Resistant Enterobacteriaceae in Surgical And Intensive Care Unit of a Hospital with
197 Low Usage of Carbapenem in Kano North West Nigeria. *Antimicrob Resistant Infect*
198 *Control*. 2013. p75.
- 199 13. Yusuf, I., Yushau,M., Sharif,A., Getso,M., Yahaya,H., Bala,J., Aliyu,I. and Haruna,M.
200 Detection Of Metallobetalactemases Among Gram-negative Bacterial Isolates From
201 Murtala Muhammad Specialist Hospital. Kano and Almadina Hospital Kaduna,
202 Nigeria. *Bayero journal of pure and applied sciences*, 2006. 5(2):84 – 88
- 203 14. Bush, K. Characterization Of B-lactamases. *Antimicrob Agents Chemother*. 1989. 33:25-
204 263
- 205 15. Luke, FC., Deveric,JA. and David, L. Overview Of The Epidemiology And The Threat Of
206 Klebsiella Pneumoniae Carbapenemases (kpc). *Resistance infect drug resist* 2012.
207 (5):133-141
- 208 16. Akujubi, CN., Ezeanya, CC. Carbapenem Susceptibility Pattern among Pseudomonas
209 aeruginosa Isolates from Clinical Specimens in South Eastern Nigeria. *Journal of*
210 *Pharmaceutical and Biomedical Sciences*.2013. 33(33):1491 -1494
- 211 17. Shamsuddeen, A. Carbapenemase Producing Gram –Negative Bacteria: An Emerging
212 Threat To Health Care In Africa. *Ann Nigerian Med-* 2013. 1 .7: (1) 1-2.